Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma

G. Fraser, P. Cramer, F. Demirkan, R. Santucci Silva, S. Grosicki, A. Pristupa, A. Janssens, J. Mayer, N. L. Bartlett, M. S. Dilhuydy, H. Pylypenko, J. Loscertales, A. Avigdor, S. Rule, D. Villa, O. Samoilova, P. Panagiotidis, A. Goy, M. A. Pavlovsky, C. KarlssonM. Hallek, M. Mahler, M. Salman, S. Sun, C. Phelps, S. Balasubramanian, A. Howes, A. Chanan-Khan

Research output: Contribution to journal › Article › peer-review

47 Scopus citations

Fingerprint

Dive into the research topics of 'Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma'. Together they form a unique fingerprint.

Medicine & Life Sciences